

Impact of the COVID-19 pandemic on antidiabetic drugs initiation in Sweden, an interrupted time series study

Nataliia Khanyk^{1,2}, Fredrik Nyberg³, Björn Wettermark¹, Huiqi Li³, Katarina Eeg-Olofsson^{4,5}, Soffia Gudbjornsdottir⁵, Mohammadhossein Hajiebrahimi¹

¹ Pharmacoepidemiology & Social Pharmacy, Department of Pharmacy, Uppsala University, Uppsala, Sweden

² Department of Pharmacy, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

³ School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

⁴ Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

⁵ Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

ORCID (email address):

NK: 0000-0002-2166-0222 (nataliia.khanyk@farmaci.uu.se)

FN: 0000-0003-0892-5668 (fredrik.nyberg.2@gu.se)

BW: 0000-0003-0531-2516 (bjorn.wettermark@farmaci.uu.se)

HL: 0000-0002-1127-0829 (huiqi.li@gu.se)

KEO: 0000-0002-3376-4707 (katarina.eeg-olofsson@vgregion.se)

SG: 0000-0000-0000-0000 (soffia.gudbjornsdottir@medic.gu.se)

MHH: 0000-0001-8118-4988 (hossein.hajiebrahimi@farmaci.uu.se)

Corresponding author:

Nataliia Khanyk
nataliia.khanyk@farmaci.uu.se
Biomedicinskt Centrum BMC, Husargatan 3,
752 37, Uppsala

Abstract:

Aim

To investigate the impact of the COVID-19-pandemic on antidiabetic drug initiation

Methods

Using Swedish national health registers, an interrupted time series study for all first-time dispensed antidiabetic drugs was performed. A minimum 14-month washout period was used. We calculated monthly cumulative incidence of antidiabetic drug initiations per 1000 population and estimated trends before and after the onset of the pandemic using segmented regression analysis.

Results

Among 167,889 participants between 1Mar2019 and 30Nov2021, male sex (53%), age 18-64 (55.3%), unmarried status (52.5%), upper secondary education level (46.2%), and being employed (53.5%) were the most frequent characteristics. Mar2020, there was an immediate level drop in antidiabetic drug initiation ($\beta_2 = -0.087\%$, $P=0.01$); however, the trend exhibited a rapid increase thereafter. Significant immediate level drops were identified for DPP4i (-0.087% , $P=0.01$), GLP1a (-0.008% , $P=0.01$) and SGLT2i (-0.033% , $P=0.003$). Older people (≥ 65) showed the largest immediate drop for antidiabetic drug initiation (-0.272% , $P=0.003$). SGLT2i demonstrated an increasing pattern both before and after the pandemic while metformin did reveal an increasing pattern among patients ≥ 65 years old after the pandemic.

Conclusion

The results identified an immediate level drop at the onset of the pandemic for any antidiabetic drug initiation, but the trend increased rapidly thereafter.

Key words: COVID-19, pandemic, antidiabetic drugs, interrupted time series

1. Introduction

The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infection named Coronavirus Disease 2019 (COVID-19) on patients with type 2 diabetes mellitus (DM2) is an important clinical challenge for both patients [1] and health services. It has been shown that COVID-19 increases the risk of new onset of DM2 [2], and conversely, pre-existing DM2 confers an increased risk of severe COVID-19, increasing the risk of hospitalization and death [3–9].

Association between particular antidiabetic drugs and COVID-19 infection or severity has been considered in some studies. Metformin, glucagon-like peptide-1 analogues (GLP1a), and sodium glucose co-transporter 2 inhibitors (SGLT2i) were found to be associated with reduced risk of COVID-19 mortality [10–12]. Insulin use might increase the risk of mortality in persons with diabetes with COVID-19 [10,13–16]. Several reviews have suggested that the effect of antidiabetic agents in patients with DM2 and COVID-19 requires further exploration, and RCTs are needed [14,17,18].

Regarding the effect of the pandemic on initiation of antidiabetic drugs, there are few studies and most indicate some significant impact on drug use [19–21]. A considerable decrease in the number of weekly insulin prescription fills was seen during, compared to before, the COVID-19 pandemic in the US (January 2019 and October 2020) [21], and lower rate of treatment initiations with antidiabetic drugs during lockdown and an increasing rate in treatment disruptions afterward was reported in France [20]. Furthermore, a temporary but statistically significant immediately decrease in antidiabetic drugs initiation at the beginning of the pandemic, followed by a significant increase in slope, was reported in Canada during the first and second quarters of the pandemic [19].

Given the relative scarcity of investigations on the impact of the COVID-19 pandemic on antidiabetic drug initiation, especially on specific antidiabetic drug classes, we aimed to examine the initiation of antidiabetic drugs in Sweden before and during the COVID-19 pandemic.

2. Materials and Methods

An interrupted time series (ITS) study was performed to evaluate changes in the incidence of new antidiabetic drug use in Sweden between 1 Jan 2018 and 30 November 2021. March 2020 was selected as the interruption point to compare trend changes before and following the onset of the pandemic. Using

Anatomical Therapeutic Chemical (ATC) codes, the first prescription of an antidiabetic drug was studied, and a minimum prior washout period without antidiabetic use was applied, see 3.1. Five different classes of antidiabetic drugs were included in the analysis: insulins and analogues (ATC code A10A), biguanide derivatives (A10BA), glucagon-like peptide-1 analogue (GLP-1a) (A10BJ), sodium-glucose co-transporter 2 inhibitors (SGLT-2i) (A10BK), and dipeptidyl peptidase 4 inhibitors (DPP4i) (A10BH) (Supplementary Table 1). Antidiabetic drug initiators who died or emigrated during each time period were included in that period but excluded from the next period, so that people who were alive and lived in Sweden at the beginning of each month were the denominator population for that month.

This study is nested in and used data from the Swedish Covid-19 Investigation for Future Insights – a Population Epidemiology Approach using Register Linkage (SCIFI-PEARL) project database [22], which now includes the entire population in Sweden linked with rich health-related and socioeconomic data, including all positive PCR tests for COVID-19. Linkage was performed using the Swedish personal identification number [23], and data are available in pseudonymized form for the SCIFI-PEARL project. Data was collected at the event time by the registers and SCIFI-PEARL received this data every 3 months. Data from the following registers were used for this study:

- The National database of notifiable diseases (SmiNet) [24] – collects data on SARS-Cov-2 test positive results since the beginning of the pandemic.
- National Prescribed Drug Register [25] – collects data for all dispensed prescription drugs in Sweden. Data are available in SCIFI-PEARL from 1 Jan 2018.
- National Patient Register [26] – collects data on inpatient and specialist outpatient care. Data are available in SCIFI-PEARL from 1 Jan 2015.
- LISA: Longitudinal Integrated database for Health Insurance and Labour Market Studies at Statistics Sweden – collects data on sociodemographic factors for all persons registered in Sweden [27].
- Total population register [28] – collects data on migration and population births and deaths.
- National Cause of Death Register [29] – collects data on all deaths including date and cause of death.

The patients dispensed antidiabetic drugs were characterized by sex (male, female), age group (<18, 18-64, and ≥65 years old), marital status (married, unmarried), educational level (up to end of lower secondary school (≤9 years), up to end of secondary school (≤12 years), tertiary school and academic (>12

years)), country of birth (Sweden, Nordics excluding Sweden, EU28 except the Nordics, Out of EU28), and employment status (unemployed including retired, employed). Furthermore, the number of different drugs dispensed other than antidiabetic drugs (0, 1, 2, 3-4, 5-9, 10-19, ≥ 20) before the start of the study period (between 1 Jan 2018, and 28 Feb 2019), as well as the number of comorbidities (1, 2, 3,4, ≥ 5) between 1 Jan 2015 and 28 Feb 2019 were calculated for all antidiabetic drug initiators in the study. We also identified the ten most frequent other non-antidiabetic drugs dispensed and ten most frequent comorbidities before the pandemic.

2.1 Statistical methods

Descriptive statistics were used to present frequency and percentage of characteristics of participants of the study. Monthly cumulative incidence rates were calculated for all new antidiabetic drug use in those that were not taking any antidiabetic drugs during the washout period. The washout period was defined as a fixed period between 1 Jan 2018 and 28 Feb 2019. Since the first prescription date for any individual has been used as their index date, the washout period will be longer for later months in the study. Cumulative incidence rates of new initiation were also calculated in the same way for new users of each separate class of antidiabetics when they were naïve for that particular antidiabetic class. Based on this definition, the study population differs for different antidiabetic drug classes, and we observe different characteristics of antidiabetic users in the study for the particular drug classes (Supplementary Table 2).

A single interrupted time series (SITSA), using a segmented regression model, estimated monthly cumulative incidence of antidiabetic drugs initiations per 1000 population [30]. Trends of antidiabetic drug initiation before and after onset of the pandemic and immediate or late trend changes were estimated. Twelve time points before the pandemic and 20 time points after the onset of the pandemic were considered in the study. The single interrupted time series analysis using segmented regression model and their contexts have been described in detail elsewhere [30]. In brief, the equation of the model was specified as follows: $y = \alpha + \beta_1 T + \beta_2 X + \beta_3 XT + \epsilon$ where y = outcome variable, α = intercept, β = coefficients (β_1 = pre-intervention trend, β_2 =level change following the intervention, β_3 = post-intervention trend, and thus $\beta_1 + \beta_3$ =post intervention slope), T = time, X = study phase, XT = time after the interruption, and ϵ = error or residual.

All analyses were performed using SAS 9.4. The research has ethics approval from the Swedish Ethical Review Authority (2020-01800 with subsequent amendments).

3. Results

The study included 167,889 individuals who initiated certain antidiabetic drugs between 1 March 2019 and 30 November 2021. Table 1 demonstrates the baseline characteristics of the participants. The median age was 62 years (IQR: 49-72). The majority of antidiabetic drug new users were born in Sweden (71.1%) while more than one fifth (21.3%) were born in countries outside the EU28. Male sex (53.0%), age 18-64 (55.3%), unmarried status (52.5%), upper secondary education level (46.2%), and being employed (53.5%), were the most frequent characteristics among the new antidiabetic drug users.

All studied types of initiated antidiabetic drugs are shown in Table 2. Overall, 91.4% of users had only one antidiabetic drug prescribed at their first visit with a new antidiabetic initiation. Metformin was the most commonly newly prescribed antidiabetic drug, found in three quarters of all study participants (75.5%) followed by insulins (10.7%), GLP-1a (5.0%), SGLT2i (4.9%), and DPP4i (2.8%). The characteristics of the study population for new initiators of each specific antidiabetic drug class are presented in Supplementary Table 2. DPP4 inhibitors were most often dispensed to new users aged over 65 (75.5%) and unemployed or retired patients (71.5%). SGLT2 inhibitors were more frequent among males (69.0%) and also among those above 65 years of age (58.0%). GLP-1a, in contrast, were most frequently initiated by patients in the 18-64 age group (84.1%) and by females (66.4%).

The number of different non-antidiabetic drug substances prescribed and number of comorbidities in the study population registered in specialist out- and inpatient care during the years before the study period are shown in Table 3. Among all antidiabetic drug users, 32.9% were dispensed 5-9 non-antidiabetics drugs and 19.0% had 3-4 drugs in the 2-year period before the study period, together more than half of all study participants. Regarding comorbidities in the 4 years and 2 months preceding the study period, more than half of participants had more than 3 comorbidity diagnoses recorded in hospital out- or inpatient care.

The results of the ITS analysis estimated an immediate significant level change in antidiabetic drug initiation following the onset of the pandemic, with the rate (β_2) dropping by -0.087% between the pre-and post-pandemic periods for all antidiabetic drugs. A significant level change was identified for the specific drug

classes of DPP4 inhibitors ($\beta_2 = -0.087\%$, $P=0.010$) (Figure 1A and Supplementary Table 3a), GLP1 analogues ($\beta_2 = -0.008\%$, $P=0.014$) (Figure 1c and Supplementary Table 3c) and SGLT2 inhibitor ($\beta_2 = -0.033\%$, $P=0.003$) (Figures 1C and Supplementary Table 3c). We did not find a significant immediate change at the start of the pandemic when we considered metformin initiation ($\beta_2 = -0.036$, $P=0.224$) or insulin treatment regardless of its indication ($\beta_2 = 0.002$, $P=0.609$). New antidiabetic drug users over 65 years old showed a stronger immediate level change, with the rate decreasing by -0.272% ($P=0.003$) for all antidiabetic drugs (Figure 1A and Supplementary Table 3a) and -0.122% for SGLT2 inhibitors ($P=0.006$) at the beginning of the pandemic (Figure 1C and Supplementary Table 3c).

Regarding the long-term trend of antidiabetic drug dispensing, initiation of all antidiabetic drugs (Figure 1A and Supplementary Tables 3a), SGLT2 inhibitors and GLP1 inhibitors showed similar pattern after the immediate change compared with the trend before the pandemic (Figure 1C and Supplementary Tables 3c). However, for metformin (among females and patients aged ≥ 65 years) (Figure 1B and Supplementary Table 3b) and for insulin (among all users, females and patients aged ≥ 65 years) (Figure 1B and Supplementary Table 3b), the initiation pattern was changed from a decreasing trend before the pandemic to an increasing pattern after the pandemic. Moreover, the initiation pattern of DPP4 inhibitors also changed from decreasing before the pandemic to increasing after the pandemic among patients at the age 18-64.

4. Discussion

In this ITS study, an immediate level drop in incidence of all antidiabetic drugs was observed at initiation of the pandemic. The level drop was notable for both sexes and stronger among patients aged ≥ 65 years. The most substantial immediate level drop occurred within the class of SGLT2 inhibitors. The level drop in SGLT2 inhibitors use was observed across both sexes and all age subgroups, but with the most prominent effect in the older population.

Considering all antidiabetic drugs, the results revealed a substantial level drop in drug initiation at the onset of the pandemic, although not statistically significant for people aged 18-64 years. This observation may suggest appropriate adherence of Swedes to the recommendations aimed to minimizing interactions during the pandemic, despite the relatively unique approach of Sweden in tackling the pandemic. Sweden did not implement a lockdown, obligatory facemasks outside healthcare, or quarantines for infected households or geographical regions, and did not close kindergartens and schools for children up to 16 during

the COVID-19 pandemic. Instead, Sweden adopted various measures with a focus on recommendations such as enhanced hygiene practices, general distance-working for employed, physical distancing in public spaces and banned visits to nursing facilities to avoid unnecessary healthcare visits and close contacts particularly for people aged 70 and above [31,32]. The results of this study might reflect this strategy in the country.

Furthermore, it was observed that the drop in the drug initiation for all antidiabetic groups at the beginning of the pandemic onset was more prominent among elderly individuals. This likely mirrors the higher vulnerability of this age group to COVID-19, where age stands out possibly as the most important factor influencing the severity of COVID-19, as was identified early on [33,34]. Moreover, the persons with diabetes were considered a risk group and advised to avoid contact with others. Therefore, patients aged over 65 may have been reluctant to locations with the potential for larger population, including healthcare and pharmacy locations, and may prefer to consult with healthcare professionals exclusively in urgent situations.

The findings also demonstrated specifically an immediate level drop in the incidence of new SGLT2 inhibitors drug dispensing at the onset of the pandemic. However, the utilization of SGLT2 inhibitors increased substantially before and during the pandemic. While the initial change in level at the onset of pandemic could be attributed to the Swedish pandemic strategy, the rise in utilization is likely associated to the new indication of the SGLT2 inhibitors for reducing cardiovascular risk in patients with diabetes [11,35,36]. The sharp increase in the trend of SGLT2 inhibitors among people aged 65 and older likely reflects the influence of these new indications [37].

The results indicated no substantial changes for metformin, despite an increasing pattern of initiation during the pandemic, particularly among individuals aged over 65. However, there was a notable increasing pattern in GLP1 dispensing, although not statistically significant, observed for both sexes and age subgroups. Similar to the SGLT2 inhibitors group, the increasing pattern seen for GLP1 analogues might be attributed to the new indication of the drug for weight reduction [38,39] and the reduction of cardiovascular risk among patients with DM2 [11,36].

Our study has several strengths including its comprehensive coverage of the Swedish population and its ability to integrate various data sources from different health registries using unique personal ID numbers. We, in fact, were thus able to include all dispensed antidiabetic drugs in Sweden in the study. Our study had

some limitations as well. The Swedish Prescribed Drug Register does not include the indication of the prescribed drugs. Therefore, it was not possible to determine the main indication for prescription of a particular drug, if there were several indications for that particular drug. Additionally, for the sub-analyses of specific antidiabetic drugs in this study, the term "new users" in the context of separate antidiabetic classes refers to individuals who were new users within their respective class but not necessarily new users of any antidiabetic medication as a whole. We also used a fixed 14-month pre-study washout period, which gives a longer washout period for later participants in the study. The 14-month was the period between 2018.01.01 (the first available drug data date in PDR) and 1 mar 2020 (the pandemic month), however, the later participants had a longer washout period. Although participants did not have the same washout period in the study, it helped us to avoid having a participants two times in the study if she/he stopped using antidiabetic for 14 months and started it again. Finally, recorded diagnoses and comorbidities were captured from the National Patent Register, which does not include primary care.

In conclusion, an immediate drop changes occurred at the onset of the pandemic, followed by a rapid return to comparable or in some instances, increased level a few months later, with the elderly population exhibiting the most pronounce changes. This pattern could be interpreted as an outcome of the pandemic-related restrictions and recommendations introduced initially in Sweden, leading to a transient reduction in visits to healthcare institution as well as pharmacies.

Funding

This work was supported by the SCIFI-PEARL project which has basic funding based on grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (Avtal om Läkarutbildning och Forskning/Medical Training and Research Agreement) grants ALFGBG-938453, ALFGBG-971130, ALFGBG-978954 and previously from a joint grant from Forte (Swedish Research Council for Health, Working Life and Welfare) and FORMAS (Forskningsrådet för miljö, areella näringar och samhällsbyggande), grant 2020-02828., as well as a grant from the Swedish Heart-Lung Foundation (20210581). This work also was supported by the Nordic COHERENCE Project, Project No. 105670 funded by NordForsk under the Nordic Council of Ministers.

Authors' relationships and activities

We declare no competing interests.

Data Availability:

The data underlying this article cannot be shared publicly due to their containing sensitive information that could compromise the privacy of research participants. Analysis data will be shared upon reasonable request to the authors. Access to similar data requires permission. Apart from ethical approval from the Swedish Ethical Review Authority, researchers will also need approval from each register holder.

Author contributions

MH, and BW wrote the protocol and designed the study. FN and BW were responsible for ethics and obtaining data. FN and HL were responsible for data linkage and compilation and basic data quality control and data management. MH has prepared the first draft of the results. MH conducted the analysis-specific data management, and statistical analyses. NK and MH prepared the first draft of the manuscript. All authors (including KEO, SG) have critically participated in reviewing and interpreting of the results and revising the manuscript. All authors have approved the final manuscript.

Declaration of Competing Interest

KEO has received fees for lecturing and/or honoraria for consulting from Sanofi, Novo Nordisk, Eli Lilly and Abbot Diabetes Care. FN has some AstraZeneca shares. The remaining authors have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors acknowledge the initial work of former master student in pharmacy Nicole Kastrati, conducted at Uppsala University (supervised by MH). The authors also acknowledge to the Nordic COHERENCE Project for supporting our study and the Wenner-Gren foundation (GFU2022-0008) for providing financial support to NK.

5. References

1. Hartmann-Boyce J, Rees K, Perring JC, Kerneis SA, Morris EM, Goyder C, et al. Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews. *Diabetes Care*. 2021/10/28 ed. 2021;44: 2790–2811. doi:10.2337/dc21-0930
2. Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after Covid-19. *Diabetologia*. 2022/03/16 ed. 2022;65: 949–954. doi:10.1007/s00125-022-05670-0
3. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *Am J Physiol Endocrinol Metab*. 2020/03/31 ed. 2020;318: E736–E741. doi:10.1152/ajpendo.00124.2020
4. Lim S, Bae JH, Kwon H-S, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat Rev Endocrinol*. 2020/11/13 ed. 2021;17: 11–30. doi:10.1038/s41574-020-00435-4
5. Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). *Diabetes Metab Res Rev*. 2020/07/20 ed. 2021;37: e3377–e3377. doi:10.1002/dmrr.3377
6. Pugliese G, Vitale M, Resi V, Orsi E. Is diabetes mellitus a risk factor for COReNaVirus Disease 19 (COVID-19)? *Acta Diabetol*. 2020/08/31 ed. 2020;57: 1275–1285. doi:10.1007/s00592-020-01586-6
7. Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era? *J Diabetes Complications*. 2020/08/26 ed. 2020;34: 107723–107723. doi:10.1016/j.jdiacomp.2020.107723
8. Bailey CJ, Gwilt M. Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin. *Front Pharmacol*. 2022;13: 784459–784459. doi:10.3389/fphar.2022.784459

9. Rawshani A, Kjölhede EA, Rawshani A, Sattar N, Eeg-Olofsson K, Adiels M, et al. Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: A nationwide retrospective cohort study. *Lancet Reg Health Eur*. 2021/04/30 ed. 2021;4: 100105–100105. doi:10.1016/j.lanepe.2021.100105
10. Chen Y, Lv X, Lin S, Arshad M, Dai M. The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis. *Front Endocrinol (Lausanne)*. 2022;13: 895458–895458. doi:10.3389/fendo.2022.895458
11. Giugliano D, Scappaticcio L, Longo M, Bellastella G, Esposito K. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off. *Cardiovasc Diabetol*. 2021;20: 205–205. doi:10.1186/s12933-021-01400-9
12. Scheen AJ. Metformin and COVID-19: From cellular mechanisms to reduced mortality. *Diabetes Metab*. 2020/08/01 ed. 2020;46: 423–426. doi:10.1016/j.diabet.2020.07.006
13. Nguyen NN, Ho DS, Nguyen HS, Ho DKN, Li H-Y, Lin C-Y, et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis. *Metabolism*. 2022/03/31 ed. 2022;131: 155196–155196. doi:10.1016/j.metabol.2022.155196
14. Kan C, Zhang Y, Han F, Xu Q, Ye T, Hou N, et al. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis. *Front Endocrinol (Lausanne)*. 2021;12: 708494–708494. doi:10.3389/fendo.2021.708494
15. Avogaro A, Bonora B, Fadini GP. Managing diabetes in diabetic patients with COVID: where do we start from? *Acta Diabetol*. 2021/06/25 ed. 2021;58: 1441–1450. doi:10.1007/s00592-021-01739-1
16. Wang W, Sun Y, Wang S, Sun Y. The Relationship Between Insulin Use And Increased Mortality In Patients With COVID-19 And Diabetes: A Meta-Analysis. *Endocrine Research*. 2021;47: 32–38. doi:10.1080/07435800.2021.1967376
17. Han T, Ma S, Sun C, Zhang H, Qu G, Chen Y, et al. Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis. *Arch Med Res*. 2021/08/09 ed. 2022;53: 186–195. doi:10.1016/j.arcmed.2021.08.002
18. Hariyanto TI, Intan D, Hananto JE, Putri C, Kurniawan A. Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression. *Diabetes Res Clin Pract*. 2021/08/28 ed. 2021;179: 109031–109031. doi:10.1016/j.diabres.2021.109031
19. Aboulatta L, Peymani P, Vaccaro C, Leong C, Kowalec K, Delaney J, et al. Drug utilization patterns before and during COVID-19 pandemic in Manitoba, Canada: A population-based study. *PLoS One*. 2022;17: e0278072–e0278072. doi:10.1371/journal.pone.0278072
20. Mathieu C, Pambrun E, Bénard-Larivière A, Noize P, Faillie J-L, Bezin J, et al. Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study. *Eur J Epidemiol*. 2022/09/21 ed. 2022;37: 1049–1059. doi:10.1007/s10654-022-00912-2
21. Yunusa I, Love BL, Cai C, Hastings T, Reeder CE, Blake EW, et al. Trends in Insulin Prescribing for Patients With Diabetes During the COVID-19 Pandemic in the US. *JAMA Netw Open*. 2021;4: e2132607–e2132607. doi:10.1001/jamanetworkopen.2021.32607
22. Nyberg F, Franzén S, Lindh M, Vanfleteren L, Hammar N, Wettermark B, et al. Swedish Covid-19 Investigation for Future Insights - A Population Epidemiology Approach Using Register Linkage (SCIFI-PEARL). *Clin Epidemiol*. 2021;13: 649–659. doi:10.2147/CLEP.S312742

23. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekblom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. *Eur J Epidemiol*. 2009/06/06 ed. 2009;24: 659–667. doi:10.1007/s10654-009-9350-y
24. Rolfhamre P, Janson A, Arneborn M, Ekdahl K. SmiNet-2: Description of an internet-based surveillance system for communicable diseases in Sweden. *Eurosurveillance*. 2006;11: 15–16. doi:10.2807/esm.11.05.00626-en
25. Wettermark B, Hammar N, MichaelFored C, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months. *Pharmacoepidemiology and Drug Safety*. 2006;16: 726–735. doi:10.1002/pds.1294
26. Ludvigsson JF, Andersson E, Ekblom A, Feychting M, Kim J-L, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. *BMC Public Health*. 2011;11: 450–450. doi:10.1186/1471-2458-11-450
27. Ludvigsson JF, Svedberg P, Olén O, Bruze G, Neovius M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. *Eur J Epidemiol*. 2019/03/30 ed. 2019;34: 423–437. doi:10.1007/s10654-019-00511-8
28. Ludvigsson JF, Almqvist C, Bonamy A-KE, Ljung R, Michaëlsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. *Eur J Epidemiol*. 2016;31: 125–136. doi:10.1007/s10654-016-0117-y
29. Brooke HL, Talbäck M, Hörnblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. *Eur J Epidemiol*. 2017/10/05 ed. 2017;32: 765–773. doi:10.1007/s10654-017-0316-1
30. Caswell - Interrupted Time Series Analysis for Single Series.pdf.
31. Ludvigsson JF. How Sweden approached the COVID-19 pandemic: Summary and commentary on the National Commission Inquiry. *Acta Paediatr*. 2022/09/15 ed. 2023;112: 19–33. doi:10.1111/apa.16535
32. Ludvigsson JF. The first eight months of Sweden’s COVID-19 strategy and the key actions and actors that were involved. *Acta Paediatr*. 2020/10/11 ed. 2020;109: 2459–2471. doi:10.1111/apa.15582
33. Brodin P. Immune determinants of COVID-19 disease presentation and severity. *Nature Medicine*. 2021;27: 28–33. doi:10.1038/s41591-020-01202-8
34. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. *Science*. 2022;375: 1122–1127. doi:10.1126/science.abm8108
35. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. *Diabetes Care*. 2023;46: S140–S157. doi:10.2337/dc23-S009
36. Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. *Kidney Int Rep*. 2022;7: 1463–1476. doi:10.1016/j.ekir.2022.04.094
37. Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*. 2021;174: 108737. doi:10.1016/j.diabres.2021.108737
38. Arnold MJ, Buelt A. SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: BMJ Rapid Recommendation. *Am Fam Physician*. 2022;105: 675–677.

39. Vosoughi K, Atieh J, Khanna L, Khoshbin K, Prokop LJ, Davitkov P, et al. Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. *EClinicalMedicine*. 2021;42: 101213–101213. doi:10.1016/j.eclinm.2021.101213

6. Tables

Table 1. Characteristics of patients with no history of antidiabetic drug use since 1 Jan 2018, at their first dispensing of any antidiabetic drug in Sweden from 1 March 2019 to 30 Nov 2021

<u>Variables</u>	<u>Numbers</u>	<u>Percent</u>	<u>P-value</u>
<u>Total</u>	167,889		
<u>Sex</u>			
Male	89,020	53.0	<0.0001
Female	78,869	47.0	
<u>Year at diagnosis</u>			
1 March 2019-28 Feb 2020	52,510	31.3	<0.0001
1 March 2020-28 Feb 2021	54,777	32.6	
1 March 2021-30 Nov 2020	60,602	36.1	
<u>Age at January 2020</u>			
<18	2,466	1.5	<0.0001
18-64	92,781	55.3	
≥65	72,642	43.3	
Median (IQR)	62 (49-72)		
Range	6-103		
<u>Marital Status at January 2020</u>			
Married	79,471	47.5	<0.0001
Unmarried	87,796	52.5	
Missing	622		
<u>Educational level at January 2020</u>			
Up to end of secondary school (9 years)	42,505	26.6	<0.0001
Up to end of upper secondary school (12 years)	73,823	46.2	
Tertiary school and Academic (More than 12 years)	43,632	27.3	
Missing	7,929		
<u>Occupation status at January 2020</u>			<0.0001
Employed	87,932	53.5	
Unemployed/Retired	76,440	46.5	
Missing	3,517		
<u>Country of birth</u>			
Sweden	119,335	71.1	<0.0001
Nordics excluding Sweden	6,192	3.7	
Eu28 except the Nordics	6,517	3.9	
Out of Eu28	35,824	21.3	
Missing	21		

Table 2: Type of antidiabetic drugs dispensed to patients with no prior antidiabetic drug history since 1 Jan 2018, at their first dispensing of any antidiabetic drug in Sweden from 1 March 2019 to 30 Nov 2021

Jan 2018, at their first dispensing of any antidiabetic drug in Sweden from 1 March 2017 to 30 Nov 2021

	<u>ATC code</u>	<u>Number</u>	<u>Percent</u>	<u>P-Value</u>
<u>Patients who were dispensed only one drug at the first prescription</u>				
		153,527		
Biguanides	A10BA	115,855	75.5	<0.0001
Insulins and analogues	A10A	16,454	10.7	
GLP-1 analogues	A10BJ	7,608	5.0	
SGLT2 inhibitor	A10BK	7,546	4.9	
DPP4 inhibitor	A10BH	4,329	2.8	
Combinations of oral blood glucose lowering drugs	A10BD	629	0.4	
Sulfonylureas	A10BB	550	0.4	
Other blood glucose lowering drugs, excl. insulins	A10BX	276	0.2	
Alpha glucosidase inhibitor (Acrobos)	A10BF	212	0.1	
Thiazolidinediones	A10BG	65	0.04	
<u>Number of antidiabetics dispensed drugs at the first prescription</u>				
1		153,527	91.5	<0.0001
2		13,177	7.9	
≥3		1,185	0.7	

GLP-1 analogues: Glucagon-like peptide-1 analogue; SGLT2 inhibitor: Sodium-glucose co-transporter 2 inhibitors; DPP4 inhibitor: Dipeptidyl peptidase 4 inhibitors

Table 3: Distribution of non-antidiabetic drug dispensing and comorbidities other than diabetes prior to the start of the study period (March 2019), among new users of antidiabetic drugs in Sweden 1 March 2019 to 30 Nov 2021

March 2019 to 30 Nov 2021

	ATC code	Number	Percent	P-Value	
<u>History of non-antidiabetic drugs dispensed before the study period</u>					
<u>(1 Jan 2018 to 28 Feb 2019)</u>					
0		26,727	15.9	<0.0001	
1		15,687	9.3		
2		16,221	9.7		
3-4		31,833	19.0		
5-9		55,237	32.9		
10-19		21,661	12.9		
≥20		523	0.3		
<u>Ten most frequent non-antidiabetic drugs dispensed before the study period</u>					
<u>(1 Jan 2018 to 28 Feb 2019)</u>					
Agents acting on the renin-angiotensin system	C09	61,491	15.7	<0.0001	
Lipid modifying agents	C10	46,835	12.0		
Beta blocking agents	C07	46,084	11.8		
Analgesics	N02	39,325	10.1		
Antithrombotic agents	B01	39,233	10.0		
Drugs for acid related disorders	A02	35,858	9.2		
Calcium channel blockers	C08	34,207	8.8		
Antibacterial for systemic use	J01	32,445	8.3		
Psycholeptics	N05	28,192	7.2		
Diuretics	C03	26,809	6.9		
<u>Number of comorbidities before the study period</u>					
<u>(1 Jan 2015 to 28 Feb 2019)</u>					
0		34,507	20.6	<0.0001	
1		23,909	14.2		
2		20,272	12.1		
3		16,718	10.0		
4		13,921	8.3		
≥5		58,562	34.9	<0.0001	
<u>Ten most frequent comorbidities before the study period</u>					
<u>(1 Jan 2015 to 28 Feb 2019)</u>					
Noninflammatory disorders of female genital tract	N80-N98	13,555	15.3	<0.0001	
Chest pain, unspecified	R074	13,501	15.3		
Other and unspecified abdominal pain	R104X	12,613	14.3		
Senile cataract	H25	11,643	13.2		
Other diseases of urinary system	N30-N39	7,101	8.0		
Dyspnea	R060	6,481	7.3		
Other disorders of the skin and subcutaneous tissue	L80-L99	6,407	7.3		
Gonarthrosis [arthrosis of knee]	M17	5,804	6.6		
Soft tissue disorders	M70-M79	5,682	6.4		
Diseases of male genital organs	N40_N51	5,583	6.3		

ATC: Anatomical Therapeutic Chemical

7. Figures




Figure 1A: Linear segmented regression analysis for cumulative incidence rate of initiating any antidiabetic drug (left), and DPP4 inhibitors (right) before and after the pandemic in Sweden. (Only statistically significant results shown); DPP4 inhibitor: Dipeptidyl peptidase 4 inhibitors




Fig. 1B: Linear segmented regression analysis for cumulative incidence rate of initiating metformin (left) and insulin (right) before and after the pandemic in Sweden, March 2019 to Nov 2021. (Only statistically significant results shown)




Fig. 1C: Linear segmented regression analysis for cumulative incidence rate of initiating GLP1 analogues (left) and SGLT2 inhibitors (right) before and after the pandemic in Sweden, March 2019 to Nov 2021. (Only statistically significant results shown); DPP4 inhibitor: Dipeptidyl peptidase 4 inhibitors

Supplementary materials

Supplementary Table 1: ATC codes for antidiabetic drugs included in the study

Groups	ATC codes
Insulin and analogues	A10A
Blood glucose-lowering agents excluding Insulin	A10B
Biguanide derivatives	A10BA
Metformin	A10BA02
Sulfonylurea compounds	A10BB
Glibenclamide	A10BB01
Peroral diabetes drugs, combinations	A10BD
Glycosidase inhibitors	A10BF
Acarbose	A10BF01
Thiazolidinediones	A10BG
Dipeptidyl peptidase 4 inhibitors (DPP-4i)	A10BH
Glucagon-like peptide-1 analogue (GLP-1a)	A10BJ
Sodium-glucose co-transporter 2 inhibitors (SGLT2i)	A10BK
Other blood glucose lowering agents excluding Insulin	A10BX

Supplementary Table 2. Characteristics of the new users of antidiabetic drugs by type of drug, in Sweden March 2019 to the end of November 2021

<u>Variables</u>	<u>Insulin</u>		<u>Metformin</u>		<u>DPP4i</u>		<u>GLP1a</u>		<u>SGLT2i</u>	
	<u>Number</u>	<u>Percent</u>	<u>Numbers</u>	<u>Percent</u>	<u>Numbers</u>	<u>Percent</u>	<u>Numbers</u>	<u>Percent</u>	<u>Numbers</u>	<u>Percent</u>
<u>Total</u>	26,530		112,158		5,650		9,161		10,234	
<u>Sex</u>										
Male	13,887	52.34	59,606	53.14	2,850	50.44	3,090	33.73	7,059	68.98
Female	12,643	47.66	52,552	46.86	2,800	49.56	6,071	66.27	3,175	31.02
<u>Age at the first dispensing date</u>										
<18	1,739	6.55	668	0.60	3	0.05	62	0.68	9	0.09
18-64	13,198	49.75	64,043	57.10	1,379	24.41	7,709	84.15	4,286	41.88
≥65	11,593	43.70	47,447	42.30	4,268	75.54	1,390	15.17	5,939	58.03
<u>Marital Status at the pandemic</u>										
Married	10,331	39.20	55,199	49.36	2,421	43.06	4,271	46.70	5,162	50.61
Unmarried	16,026	60.80	56,632	50.64	3,202	56.94	4,874	53.30	5,037	49.39
Missing	173		327		27		16		35	
<u>Educational level at the pandemic</u>										
Secondary school (9 years)	7,206	30.31	27,956	25.87	2,055	37.64	1,500	16.74	2,694	27.06
Upper secondary school (12 years)	10,554	44.39	50,522	46.76	2,289	41.93	4,096	45.70	4,671	46.92
Academic education (>12 years)	6,018	25.31	29,574	27.37	1,115	20.42	3,367	37.57	2,591	26.02
Missing	2,752		4,106		191		198		278	
<u>Occupation status at the pandemic</u>										
Employed	11,376	45.98	61,306	55.32	1,592	28.50	6,835	75.15	4,796	47.35
Unemployed/Retired	13,367	54.02	49,514	44.68	3,993	71.50	2,260	24.85	5,333	52.65
Missing	1,787		1,338		65		66		105	
<u>Country of birth</u>										
Sweden	19,600	73.90	78,215	69.74	4,575	80.99	6,239	68.13	8,200	80.13
Nordics excluding Sweden	984	3.71	4,064	3.62	249	4.41	282	3.08	464	4.53
Eu28 except the Nordics	966	3.64	4,328	3.86	199	3.52	459	5.01	367	3.59
Out of Europe	4,974	18.75	25,541	22.77	626	11.08	2,178	23.78	8,200	80.13
Missing	6		10		1		3		1	

GLP-1 analogues: Glucagon-like peptide-1 analogue; SGLT2 inhibitor: Sodium-glucose co-transporter 2 inhibitors; DPP4 inhibitor: Dipeptidyl peptidase 4 inhibitors

Supplementary Table 3a: Single ITS analysis (SITSA) for cumulative incidence rate of any antidiabetic drug and DPP4i initiation before and after the pandemic in Sweden

Antidiabetic drugs				DPP4i		
	Estimate	P-value	95% CI	Estimate	P-value	95% CI
β_0	0.405	<0.0001	0.346-0.463	0.405	<.0001	0.346-0.463
β_1	0.002	0.585	-0.006-0.010	0.002	0.585	-0.006-0.01
β_2	-0.087	0.010	-0.148- (-0.025)	-0.087	0.010	-0.148-(-0.025)
β_3	0.015	0.009	0.004- 0.025	0.015	0.009	0.004-0.025
$\beta_1+\beta_3$	0.017	<0.0001	0.012- 0.022	0.017	<.0001	0.012-0.022
Male						
β_0	0.411	<0.0001	0.345-0.477	0.043	<.0001	0.036-0.050
β_1	0.004	0.404	-0.005-0.013	0.0004	0.317	-0.0004-0.001
β_2	-0.10	0.011	-0.173-(-0.028)	0.0006	0.871	-0.006-0.007
β_3	0.015	0.019	0.003-0.027	-0.0004	0.379	-0.001-0.001
$\beta_1+\beta_3$	0.019	<0.0001	0.013-0.025	0.00001	0.948	-0.0004-0.0004
Female						
β_0	0.39	<0.0001	0.347-0.444	0.040	<.0001	0.037-0.042
β_1	0.0005	0.883	-0.006-0.007	0.0002	0.314	-0.0002-0.001
β_2	-0.07	0.012	-0.121-(-0.019)	-0.001	0.658	-0.007-0.004
β_3	0.015	0.002	0.007-0.024	0.0002	0.455	-0.0003-0.001
$\beta_1+\beta_3$	0.016	<0.0001	0.012-0.019	0.0004	0.083	-0.0001-0.001
Age 18-64						
β_0	0.323	<.0001	0.278-0.368	0.018	<.0001	0.016-0.020
β_1	0.006	0.0637	-0.0001-0.012	0.0008	<.0001	0.001-0.001
β_2	-0.049	0.0614	-0.098-0.0003	-0.001	0.511	-0.005-0.002
β_3	0.010	0.0235	0.002-0.018	-0.0007	0.006	-0.001-(-0.0002)
$\beta_1+\beta_3$	0.016	<.0001	0.012-0.019	0.0002	0.209	-0.0001-0.0004
Age => 65						
β_0	1.043	<.0001	0.885-1.201	0.156	<.0001	0.136-0.176
β_1	-0.008	0.456	-0.029-0.013	-0.001	0.400	-0.004-0.002
β_2	-0.272	0.003	-0.435-(-0.108)	-0.001	0.915	-0.024-0.022
β_3	0.046	0.003	0.019-0.074	0.002	0.212	-0.001-0.005
$\beta_1+\beta_3$	0.038	<.0001	0.025-0.051	0.0009	0.243	-0.001-0.002

β_0 : Constant value; β_1 : Pre- Trend slop; β_2 : Post- Level Change; β_3 : Post- Trend Change; $\beta_1+\beta_3$: Post- Trend slop; CI: 95% Confidence interval; DPP4: Dipeptidyl Peptidase-4 Inhibitors

Supplementary Table 3b: Single ITS analysis (SITSA) for cumulative incidence rate of Metformin and Insulin before and after the pandemic in Sweden

	Metformin			Insulin		
	Estimate	P-value	95% CI	Estimate	P-value	95% CI
β_0	0.417	<.0001	0.362-0.471	0.068	<.0001	0.064-0.071
β_1	-0.004	0.268	-0.011-0.003	-0.0005	0.038	-0.001-(-0.0001)
β_2	-0.036	0.224	-0.093-0.021	0.002	0.609	-0.006-0.011
β_3	0.007	0.083	-0.0007-0.015	0.001	0.009	0.0003-0.007
$\beta_1+\beta_3$	0.003	0.046	0.00006-0.006	0.0004	0.156	-0.0002-0.001
Male						
β_0	0.454	<.0001	0.392-0.515	0.074	<.0001	0.066-0.082
β_1	-0.005	0.272	-0.013-0.003	-0.0009	0.117	-0.002-0.0002
β_2	-0.039	0.256	-0.104-0.027	0.004	0.576	-0.010-0.018
β_3	0.007	0.132	-0.002-0.016	0.001	0.120	-0.0002-0.002
$\beta_1+\beta_3$	0.003	0.157	-0.001-0.006	0.00006	0.884	-0.001-0.001
Female						
β_0	0.385	<.0001	0.339-0.431	0.065	<.0001	0.063-0.068
β_1	-0.004	0.192	-0.010-0.002	-0.0004	0.017	-0.0008-(-0.0001)
β_2	-0.032	0.194	-0.081-0.015	0.002	0.570	-0.004-0.008
β_3	0.008	0.021	0.002-0.015	0.001	0.001	0.0005-0.002
$\beta_1+\beta_3$	0.004	0.002	0.001-0.007	0.0006	0.015	0.0001-0.001
Age 18-64						
β_0	0.372	<.0001	0.329-0.415	0.061	<.0001	0.057-0.065
β_1	-0.002	0.561	-0.007-0.004	-0.00003	0.890	-0.001-0.0004
β_2	-0.012	0.625	-0.059-0.035	0.002	0.711	-0.007-0.011
β_3	0.005	0.169	-0.002-0.011	0.0008	0.070	-0.00003-0.002
$\beta_1+\beta_3$	0.003	0.032	0.0002-0.006	0.0008	0.039	0.00004-0.001
Age => 65						
β_0	0.991	<.0001	0.852-1.131	0.138	<.0001	0.123-0.153
β_1	-0.017	0.077	-0.035-0.001	-0.003	0.010	-0.005-(-0.0008)
β_2	-0.141	0.070	-0.287-0.006	0.002	0.898	-0.022-0.025
β_3	0.025	0.020	0.005-0.045	0.003	0.003	0.001-0.006
$\beta_1+\beta_3$	0.008	0.043	0.0002-0.016	0.0006	0.356	-0.001-0.002

β_0 : Constant value; β_1 : Pre- Trend slop; β_2 : Post- Level Change; β_3 : Post- Trend Change; $\beta_1+\beta_3$: Post- Trend slop; CI: 95% Confidence interval;

Supplementary Table 3c: Single ITS analysis (SITSA) for cumulative incidence rate of GLP1 agonist and SGLT2 inhibitors initiation before and after the pandemic in Sweden

<u>GLP1a</u>				<u>SGLT2i</u>		
	<u>Estimate</u>	<u>P-value</u>	<u>95%CI</u>	<u>Estimate</u>	<u>P-value</u>	<u>95%CI</u>
β_0	0.029	<.0001	0.024-0.033	0.020	<.0001	0.016-0.024
β_1	0.001	0.0001	0.0008-0.002	0.002	<.0001	0.002-0.003
β_2	-0.008	0.014	-0.015-(-0.002)	-0.033	0.003	-0.054-(-0.013)
β_3	0.002	<.0001	0.001-0.003	0.005	0.000	0.003-0.007
$\beta_1+\beta_3$	0.003	<.0001	0.003-0.004	0.007	<.0001	0.009-0.009
Male						
β_0	0.024	<.0001	0.018-0.031	0.016	0.0004	0.008-0.024
β_1	0.001	0.002	0.0006-0.002	0.004	<.0001	0.003-0.005
β_2	-0.010	0.023	-0.018-(-0.002)	-0.051	0.002	-0.079-(-0.022)
β_3	0.002	0.004	0.0007-0.003	0.006	0.003	0.002-0.009
$\beta_1+\beta_3$	0.003	<.0001	0.003-0.004	0.010	<.0001	0.007-0.013
Female						
β_0	0.034	<.0001	0.030-0.039	0.015	<.0001	0.010-0.020
β_1	0.001	0.001	0.0005-0.002	0.001	0.0002	0.0008-0.002
β_2	-0.006	0.073	-0.013-0.0003	-0.021	0.010	-0.036-(-0.006)
β_3	0.003	<.0001	0.002-0.004	0.003	0.005	0.001-0.005
$\beta_1+\beta_3$	0.004	<.0001	0.003-0.004	0.004	<.0001	0.003-0.006
Age 18-64						
β_0	0.034	<.0001	0.027-0.041	0.011	<.0001	0.007-0.015
β_1	0.001	0.005	0.0006-0.002	0.003	<.0001	0.002-0.003
β_2	-0.005	0.271	-0.014-0.004	-0.015	0.004	-0.024-(-0.005)
β_3	0.003	<.0001	0.0019-0.005	0.001	0.072	-0.00006-0.002
$\beta_1+\beta_3$	0.005	<.0001	0.004-0.006	0.004	<.0001	0.003-0.005
Age => 65						
β_0	0.052	<.0001	0.042-0.063	0.041	<.0001	0.027-0.056
β_1	0.0006	0.393	-0.0008-0.002	0.005	<.0001	0.003-0.007
β_2	-0.013	0.110	-0.028-0.002	-0.122	0.006	-0.202-(-0.042)
β_3	0.002	0.006	0.0008-0.004	0.017	0.001	0.008-0.025
$\beta_1+\beta_3$	0.003	<.0001	0.002-0.004	0.022	<.0001	0.014-0.030

β_0 : Constant value; β_1 : Pre- Trend slop; β_2 : Post- Level Change; β_3 : Post- Trend Change; $\beta_1+\beta_3$: Post- Trend slop; SGLT2 inhibitor: Sodium-glucose co-transporter 2 inhibitors; CI: 95% Confidence interval; GLP1: glucagon-like peptide 1 agonists